Abscopal Effect and Resistance Reversion in Nivolumab-Treated Non-Small-Cell Lung Cancer Undergoing Palliative Radiotherapy: A Case Report
Francesco Fiorica(University of Verona), Carlotta Giorgi(University of Ferrara), Michèle Milella(National Cancer Institute), Jacopo Giuliani(University of Ferrara), Sara Pilotto(University of Verona), Lorenzo Belluomini(University of Ferrara), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Benedetta Urbini(Ospedale Sant'Anna)
Cited by 8
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
PTEN: Multiple Functions in Human Malignant Tumors
|Frontiers in Oncology|2015|460